Company intelligence
biomindz
Mainz. The Place to biotech. Europe's Life Science Hub for Research, Innovation & Growth
About biomindz
Who we are: biomindz is the municipally owned life science development company of the City of Mainz. We develop, connect and promote one of Europe's fastest-growing Life Science Ecosystems by bringing together academia, industry, government and investors. Our mission is to create the conditions where scientific discoveries become medical breakthroughs, entrepreneurial success and better health for people around the world. We build ecosystems. We enable innovation. We create impact. +++++++++++ Why entrepreneurs and scientists choose Mainz: Mainz is the place to biotech. Home to BioNTech, TRON, Johannes Gutenberg University and the University Medical Center Mainz, Mainz combines world-class science, entrepreneurial ambition and global industry leadership. Whether you are expanding into Europe, establishing a new R&D location or looking for strategic research partners, Mainz offers an ideal environment to research, innovate and grow. +++++++++++ How biomindz supports your growth: From site selection and laboratory space to strategic partnerships, funding opportunities, talent access and international visibility, biomindz supports companies throughout every stage of their growth journey. From the first conversation to long-term growth, we remain your trusted partner in Mainz. +++++++++++ Click here for our netiquette: https://biomindz.com/netiquette
Verified activity
Signals from biomindz
7 published signals
Presence & Recognition
biomindz hosted the 14th Life Science & Biotech Meetup at the Mainz The Place to Biotech hub alongside Boehringer Ingelheim to gather people from across the ecosystem.
Reported by biomindz
Presence & Recognition
biomindz participated in the 13th rocon Firmenlauf (Corporate Run) in Mainz, running for the Firmenlauf Mainz 2026 after participating in the Gutenberg Halfmarathon in May.
Reported by biomindz
Capital & Finance
biomindz reported that Prof. Edward Lemke and Prof. Michael Kühn from Johannes Gutenberg-Universität Mainz and Universitätsmedizin Mainz received around €460,000 in EFRE funding from the European Union and the State of Rhineland-Palatinate for their joint research project on developing a Menin inhibitor for acute myeloid leukemia.
Reported by biomindz
Presence & Recognition
biomindz welcomed colleagues and partners from Marburg, INNEXIS Group, CSL and Wirtschaftsförderung Marburg to Mainz last Friday.
Reported by biomindz
Presence & Recognition
biomindz has a presence at the Mainz Life Science and Biotechnology location with Universitätsmedizin Mainz, TRON-Mainz, and BioNTech SE.
Reported by Mike Peter Schweitzer
Presence & Recognition
biomindz attended the keynote speech by Thomas Müller from the Bundesministerium for Health.
Reported by Mike Peter Schweitzer
Presence & Recognition
biomindz attended the 15th anniversary of the House of Pharma & Healthcare in Frankfurt and the keynote speech by Shashank Deshpande, Chairman of the Board of Managing Directors and Head of Human Pharma at Boehringer Ingelheim.
Reported by Mike Peter Schweitzer